Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ripply transcriptional repressor 1 (RIPPLY1) is a nuclear protein that acts as a transcriptional repressor, particularly by interacting with the transcriptional corepressor Groucho[5]. It is essential for the proper transition from presomitic mesoderm to somites during embryonic development, terminating segmental gene expression and maintaining the rostrocaudal polarity of somites[5][3][4][2]. RIPPLY1 is expressed in the nucleus of developing tissues and is involved in negative regulation of transcription, somite boundary formation, and skeletal muscle development[2][3][4]. Mutations in the human ortholog are implicated in certain congenital vertebral malformation syndromes, such as spondylocostal dysostosis[2]. There is no current evidence indicating that RIPPLY1 is a direct therapeutic target or interacts with drugs in clinical use[4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ripply transcriptional repressor 1 (RIPPLY1).